1. Home
  2. CGEM vs TALK Comparison

CGEM vs TALK Comparison

Compare CGEM & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.18

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Talkspace Inc.

TALK

Talkspace Inc.

HOLD

Current Price

$5.19

Market Cap

788.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
TALK
Founded
2016
2012
Country
United States
United States
Employees
N/A
521
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
788.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CGEM
TALK
Price
$16.18
$5.19
Analyst Decision
Strong Buy
Buy
Analyst Count
8
6
Target Price
$30.13
$6.42
AVG Volume (30 Days)
778.1K
1.3M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.02
Revenue Next Year
$5.20
$21.24
P/E Ratio
N/A
$155.55
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$2.22
52 Week High
$16.74
$5.20

Technical Indicators

Market Signals
Indicator
CGEM
TALK
Relative Strength Index (RSI) 65.46 57.77
Support Level $11.92 $4.59
Resistance Level N/A $5.19
Average True Range (ATR) 1.02 0.02
MACD 0.27 -0.01
Stochastic Oscillator 92.55 50.00

Price Performance

Historical Comparison
CGEM
TALK

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

Share on Social Networks: